Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | TPH1 | P17752 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063752 | 0.87 | DPP4 (0.47) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL588955 | 0.78 | DPP4 (0.43) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 | |
| Trifluoroacetic Acid SCHEMBL4544157 | 0.76 | SLC6A4 (0.58) | DPP4GRB2PTPN1ANPEPENPEP | |
| Trifluoroacetic Acid SCHEMBL27504179 | 0.74 | KEAP1 (0.46) | SLC1A3SLC1A2SLC1A1ALOX5CPB2 | |
| SCHEMBL537570 | 0.74 | SLC7A5 (0.58) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL537569 | 0.74 | SLC7A5 (0.58) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL588601 | 0.74 | SLC7A5 (0.58) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 | |
| Trifluoroacetic Acid SCHEMBL4358439 | 0.73 | GRB2 (0.40) | DPP4SLC1A1GRB2PTPN1ANPEP | |
| Trifluoroacetic Acid SCHEMBL4358433 | 0.73 | GRB2 (0.40) | DPP4SLC1A1GRB2PTPN1ANPEP | |
| SCHEMBL2671472 | 0.72 | CYP1A2 (0.46) | DPP4SLC1A3SLC1A2SLC1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2010185-B1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| EP-2010185-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | DPP4 19/4885SLC1A3 3978/4885SLC1A2 4326/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | DPP4 920/4885SLC1A3 3099/4885SLC1A2 3054/4885 |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | DPYD, TYMS, TPMT | DPP4 1190/4885SLC1A3 3244/4885SLC1A2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.